Dutch microRNA drug developer InteRNA Technologies this week announced that it has formed a sponsored-research agreement with the Dana-
Farber Cancer Institute to develop cancer therapeutics targeting the small, non-coding RNAs.Under the deal, InteRNA’s ...
[GenomeWeb - 11/05/2009]